NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization30.97 mln
Float3.85 mln
Earnings Date04/23/2027
EPS
364
Exceptional
P / E
0.00
Anomalous
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
80.00
Transformational upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
Business Description
Enlivex is an Israeli biotech company founded in 2005 and based in Ness Ziona, focused on developing a cell-based therapy called Allocetra that works by retraining the immune system's macrophage cells to behave normally. The company is currently running clinical trials to test Allocetra across several serious medical conditions, including knee and jaw joint deterioration, as well as life-threatening organ failure caused by sepsis. Its work sits at an early but promising stage, with multiple studies underway to establish the safety and effectiveness of its approach.